Author: Charmaine Fraser

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, provides the following update on current trading.   Despite having a strong pipeline of potential new business, several large contracts have taken longer than expected to be signed and as a result the Company’s total income for the financial year ending 30 June 2024 (“FY24”)...

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, recently provided a brief update in-line with its interim results via Investor Meet Company and has updated its website with the presentation.   The presentation and Q&A from the meeting are now available at the Company’s website: https://www.physiomics.co.uk/portfolio-item/investor-presentation-interim-results-and-company-update/     Enquiries:   Physiomics plc Dr Jim Millen, Non-Executive Chairman, +44 (0)1235...

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been awarded a substantial new contract by an existing large pharma client.  The project involves Pharmacokinetic-Pharmacodynamic (PKPD) modelling in the field of DNA damage/ repair field and will help inform clinical dose and scheduling decisions. The value...

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it will be posting its interim results on Thursday 7 March 2024.   The Company will provide a live presentation update in-line with these results via Investor Meet Company on 18 March 2024 at 12:00 pm GMT. During this presentation,...